{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026708","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.584965+00:00","generated_at":"2026-05-24T08:48:32.798231+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal","bullets":["Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.","Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.","Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.","Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.","No assurance that Company will ultimately regain compliance and remain listed on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026708","json":"https://secwatch.observer/filing/0001104659-25-026708.json","markdown":"https://secwatch.observer/filing/0001104659-25-026708.md","text":"https://secwatch.observer/filing/0001104659-25-026708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/0001104659-25-026708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/tm259958d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:48:32.798231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}